8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  January 14, 2009

BRUKER CORPORATION
(Exact name of registrant as specified in its charter)

Delaware	000-30833	04-3110160
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)
40 Manning Road Billerica, MA 01821 (Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (978) 663-3660

Check the appropriate box if the Form 8-K filing is intended to simultaneously satisfy the reporting obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act

o Soliciting material pursuant to Rule 14a-12 of the Exchange Act

o Pre-commencement communications pursuant to Rule 14d-2(b) Exchange Act

o Pre-commencement communications pursuant to Rule 13e-4(c) Exchange Act

Item 2.02Results of Operations and Financial Condition.

On January 14, 2009, Bruker Corporation (the “Company”) will participate in the 27th Annual J.P. Morgan Healthcare Conference in San Francisco, California.  The presentation materials, a copy of which are attached hereto as Exhibit 99.1, on slide 12 contain previously non-public information relating to (i) preliminary, unaudited revenue estimates, (ii) further net debt reduction, and (iii) qualitative comments on order bookings in the recently completed fourth quarter of fiscal 2008.

The information in this Current Report on Form 8-K, including exhibits attached hereto and the information under Item 7.01 below, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be deemed incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, unless specifically identified therein as being incorporated by reference therein.

Item 7.01Regulation FD Disclosure.

The information set forth in Item 2.02 is incorporated herein in its entirety. The slides that will accompany Company management’s presentation at the above-referenced conference, attached to this Current Report on Form 8-K as Exhibit 99.1, are also posted on the Company’s investor relations website at http://www.bruker.com.

Item 9.01Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. 99.1 January 14, 2009 Presentation at the 27th Annual J.P. Morgan Healthcare Conference.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BRUKER CORPORATION
	(Registrant)
Date: January 14 , 2009	By:
		/s/ Frank H. Laukien
		Frank H. Laukien, Ph.D.
		Chief Executive Officer and President

3

EX-99.1

Exhibit 99.1

Bruker Corporation (BRKR) Presentation at 27th J.P. Morgan Healthcare Conference January 14, 2009 Frank Laukien, President & CEO William Knight, Chief Financial Officer  Stacey Desrochers, Treasurer & Director of IR

Bruker Corporation  Safe Harbor Statement  Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the integration of businesses we have acquired or may acquire in the future, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing, competition, dependence on collaborative partners and key suppliers, capital spending and government funding policies, changes in governmental regulations, intellectual property rights, litigation, and exposure to foreign currency fluctuations. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our recent Proxy Statements on Schedule 14A, our annual report on Form 10-K for the year ended December 31, 2007, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements other than as required by law.  

Bruker Corporation Today  Life Science Tools and Analytical Solutions High-Performance Technology Platforms Bruker AXS Materials Research & Elemental Analysis X-ray Diffraction X-ray Crystallography X-ray Fluorescence EDS/EBSD, XRF Microanalysis OES & Combustion Analysis Atomic Force Microscopy Bruker Daltonics Mass Spectrometry & CBRNE Detection MALDI-TOF(/TOF) Ion Trap MSn ESI-(Qq)-TOF FTMS GC/MS IMS FT-IR NAA Bruker Optics Vibrational Spectroscopy FT-IR & Microscopy FT-NIR Raman & Microscopy TD-NMR Bruker BioSpin Magnetic Resonance & Magnets NMR MRI EPR Supercon Magnets 

1. Bruker makes major, long-term investments for quantum leaps in technology and capabilities Leadership in innovation, major investment in R&D  Leading market positions in key segments  2. Bruker is a fast growing company with high margin goals Global distribution, attractive markets, excellent Bruker brand  Fast organic growth, disciplined M&A, margin expansion  3. Bruker is investing heavily in new break-out opportunities for fast growth and high margins Molecular Research in Chemistry & Proteomics Materials Research and Nanotechnology CBRNE Detection for Homeland Security Superconductors, Magnets and HTS Devices IVD, Molecular Imaging & Clinical Microbiology Bruker’s Philosophy and Vision: Leadership in High-Performance Scientific Instruments & Analytical Solutions

5 Quantum Jumps in Performance Bruker BioSpin’s Global Technology and  Market Leadership in NMR and EPR Spectroscopy Founded in 1960 by Prof. Guenther Laukien (in picture) 1960-1990: pioneered FT-NMR, supercon magnets,  leadership in other key technologies 1990-2008: pioneered shielded magnets, 2K ultra-high field magnets (750-950 MHz), digital NMR spectrometer, and CryoProbes™ for major leaps forward   Bruker BioSpin 2008: Introduced Avance III – fastest NMR system NMR CryoProbe won a 2008 R&D 100 Award Installed world’s first shielded 950 MHz at NCRC November 2008: Saudi KAUST order of  10 NMR systems for ~$20M

1 Quantum Jumps in Performance Bruker BioSpin’s Global Technology and Market Leadership in Research MRI Pioneered actively-shielded, refrigerated superconducting MRI magnets Collaboration with Siemens Medical on ClinScan™ pre-clinical MRI system Pioneered cryogenic MRI probes for major sensitivity boost MRI MicroCryoProbe won 2008 R&D 100 Award 2009: entering market for ultra-high field magnets for human MRI as OEM supplier

Quantum Jumps in Performance X2S for Routine Chemical Crystallography SMART X2S (crystal-to-structure) System World’s First Automated Molecular Structure Machine Fully-automated small molecule 3D structure determination: structures at the touch of a button for working chemists anywhere Simple, cost-effective benchtop system For academic or industrial chemistry labs without staff crystallographers Pittcon 2008 Editors’ Gold Award R&D Magazine 2008 R&D 100 Award SMART X2S

 Quantum Jumps in Performance Trace Elemental Analysis with TXRF New S2 PICOFOX Benchtop TXRF Ultra-trace analysis for: Pharmaceutical raw material purity tests, Environmental monitoring, Food safety, Biofuels, Mining Utilizes Bruker’s Patented XFlashTM Silicon Drift Detector (SDD) Technology for Unprecedented Specificity and Speed Highly attractive alternative to ICP and AA No calibration and no consumables Cost-effective benchtop/portable system Pittcon 2008 Editors’ Bronze Award S2 PICOFOX

 Quantum Jumps in Performance First Handheld XRF with SDD uXRF Jewelry Analyzer New TRACERturbo Handheld XRF Dramatically improved speed, sensitivity and energy resolution with XFlashTM Silicon Drift Detector (SDD) Breakthrough for light element analysis Art conservation, archaeology, aerospace, metals markets, environmental analysis New M1 MISTRAL Tabletop uXRF Launched this week at ARABLAB in Dubai For jewelry and precious metals analysis Large sample compartment for irregular objects Microscope with ‘crosshair’ for exact localization

Quantum Jumps in Performance maXis™ UHR-TOF launched at ASMS 2008 A new category of UHR-TOF mass specs: Ultra-high resolution 40-60k Broad mass range and high mass Mass accuracy in MS & MS/MS <1ppm High speed at 20 full spectra/sec Isotopic fidelity for molecular formulae ... simultaneously! (not possible with any other MS) Bruker has ‘rewritten the book’ with UHR-TOF technology: dramatic change in high-performance MS market Excellent market reaction and maXis orders Recent FTMS/maXis order from Washington U. (M. Gross) Successful installations in Europe, USA, Pacific Rim Professor Jeff Gorman with maXis at Queensland Institute of Medical Research (QIMR)

Global Company with Diversified Markets  Excellent Reputation in High-Performance  Life Science Tools and Analytical Solutions  Other Significant R&D,  Production Sites Direct Sales Offices Major DE, CH & FR R&D and Production Sites Additional distributors  around the world Headquarters Markets:  Life science & Clinical Research Pharma & Biotech  Materials Research & Nanotech Food & Environmental Quality & Process Control Homeland Security & forensics

Growth and Margins Key Financials & Revenue Growth BRKR 2007 Financials (incl. Bruker BioSpin acquisition in Febr. 2008): Revenue $1.032 billion ($851M in 2006) 21% growth (15% FX-adjusted) Net income $97 million ($75M in 2006) EPS $0.59 ($0.47 in ‘06) Free Cash Flow $102M ($62M in 2006) YTD Q3-08 y-o-y revenue growth is 15% (6% FX-adjusted) Q4-08 and FY08 Financial Results expected in late February 2009. Preliminary Flash for Q4-08 (unaudited, subject to change): Revenue >$300M (significantly higher than Q3-08 revenue of $242M) Net debt reduced to <$100M Healthy order bookings overall (some weak spots, many areas of strength) $688 $792 0.0 200.0 400.0 600.0 800.0 YTD Q3-07 YTD Q3-08

Growth and Margins Profitability & Margin Opportunities Good margin progress in 2005-2007, but newer Bruker Daltonics, Bruker AXS and Bruker Advanced Supercon Businesses have not reached longer-term financial metrics yet. BRKR operating margin YTD Q3-08 was 8.3% (excl. acquisition expenses) cost-cutting & tax initiatives for margin expansion: increased to >$20M p.a. including voluntary CEO and CFO 2009 temporary salary reductions Gross margins YTD Q3-08 of 44.4% (consistent with YTD Q3-07) medium-term goal is GM of >50% Strong R&D investment of 12.8% YTD Q3-08 to capitalize on significant opportunities medium-term goal: 10% Opportunities to leverage YTD Q3-08 S,G&A of 23.4% medium-term goal: 20-22% Adj. EBITDA Adj. Operating Income $72 $109 $66 $106 $0 $25 $50 $75 $100 $125 YTD Q3-07 YTD Q3-08

Growth and Margins  GAAP Reconciliation We believe the inclusion of the non-GAAP measures helps investors to gain a better understanding of our core operating results and future prospects, consistent with how management measures and forecasts the Company’s performance, especially when comparing such results to previous periods or forecasts. However, the non-GAAP financial measures included here are not meant to be a better presentation or a substitute for results prepared in accordance with GAAP. 2006 2007 2007 2008 GAAP Operating Income 107.0 $                    135.1 $                    71.3 $                      59.5 $                      Acquisition related charges 5.7                            7.4                            0.5                            6.2                            Adjusted Operating Income 112.7                        142.5                        71.8                          65.7                          Depreciation and amortization 25.4                          27.9                          21.1                          21.9                          Write-down of demonstration     equipment 22.2                          21.2                          16.2                          18.5                          Adjusted EBITDA 160.3 $                    191.6 $                    109.1 $                    106.1 $                    GAAP Net Income 74.8 $                      97.2 $                      58.7 $                      38.8 $                      Acquisition related charges 5.0                            7.4                            0.5                            6.2                            Adjusted Net Income 79.8 $                      104.6 $                    59.2 $                      45.0 $                      Diluted Shares Outstanding 160.1                        164.3                        164.0                        165.6                        Earnings per share, GAAP 0.47 $                      0.59 $                      0.36 $                      0.23 $                      Earnings per share, Adjusted 0.50 $                      0.64 $                      0.36 $                      0.27 $                      Year Ending December 31, Nine Months Ended September 30,

Investment in New Opportunities: Melamine and Cyanuric Acid Detection in 5 Minutes using LC/MS/MS Bruker Daltonics recently introduced a rapid, cost-effective solution for melamine detection based on high-capacity ion-trap mass spectrometry Continued strong push into applications development and applied markets HCTultra Ion Trap Mass Spec

Investment in New Opportunities: New Japan National Police Agency (NPA) Order for 51 Mass Spectrometers The Japanese National Police Agency (NPA) signed a $12M contract for 51 Bruker micrOTOF II ESI-TOF mass spectrometers, plus associated LC and CE equipment, to be used for: Exact Mass Analysis and Automated Molecular Formula Determination in: drugs/metabolites in urine food safety analysis forensic toxicology environmental testing microTOF II ESI TOF Mass Spec

17 Investment in New Opportunities:  Complete Molecular Confidence™  Integrated Solution for Chemistry & Metabolomics Integrated  Sample Submission  and Tracking NMR and Exact Mass MS Molecular  Profile Report Additional Techniques: SCD, FT-IR a major step towards automated molecular formula determination and structure verification - only from Bruker

 Investment in New Opportunities: Bruker Acquires Atomic Force Microscopy (AFM) Company in August 2008 for Nanotechnology Well-established method for ultra-high spatial resolution surface imaging Materials research applications like semiconductors, data storage, electronic materials, and solar cells Product range from bench-top high-performance AFM-only microscopes to integrated high-end AFM/optical microscopy (OM) combinations, to large floor-standing AFM/OM combinations for 300mm wafer characterization Annual revenue ~$3M, expected to grow with Bruker AXS global distribution and service The global AFM/SPM market had an estimated total market size of  >$250 million NANOStation II combines AFM and OM in a very compact set-up

Investment in New Opportunities: Bruker Detection Division in CBRNE Detection for Defense and Homeland Security New IMS explosives detection products being launched in 2009 Large Opportunity in CWA/TIC Facilities Monitoring (DHS Phase III) NEW: DEtector™ Drugs and Explosives detection RAID-M Portable IMS for CWAs and TICs gas/vapor detection HAWK FR Stand-off detector for chemical cloud detection Mobile-IR Portable FT-IR identification of Unknown powders/chemicals

20 Advanced low-temperature superconducting (LTS) wires for clinical MRI, NMR, EPR and FTMS magnets LTS wires for magnets used in physics accelerators or nuclear fusion projects Medium-temperature superconductors (MTS) MgB2 wires for future cryofree MRI magnets 1G BSSCO and 2G YBCO high-temperature superconductors (HTS) and cables Next-generation industrial magnets: partnerships for HTS industrial motors & generators HTS Devices, e.g. new Superconducting     Fault Current Limiters (SFCL) for energy grid stabilization, high-energy and MRI HTS Current Leads (CL), SMES, etc.  Investment in New Opportunities: Bruker Advanced Supercon Business Superconducting Wires and Magnets

Investment in New Opportunities: Bruker MALDI Molecular Imager™ MALDI Tissue Imaging and Molecular Histology Complete MALDI Molecular Imaging Solution:  For proteins, peptides, lipids, small molecules New: FTMS Imaging of drugs and metabolites  in tissues at therapeutic dosing levels ImagePrep™ Sampling Robot MALDI-TOF (/TOF)  or MALDI-FTMS with proprietary smartbeam™ laser FlexImaging Software ClassImaging Algorithms

Investment in New Opportunities: MALDI Biotyper for Microorganism Rapid, High-Specificity ID at Low Cost Highly specific species ID of bacteria, fungi ID in mixtures Minimal sample prep, fast results Proprietary, high quality protein fingerprint database Low cost per analysis (compared to biochemical or PCR) Better, Faster, Cheaper! Select Colony & prepare MALDI target plate Generate MALDI-TOF data, automated ID from proprietary database

www.bruker.com